Table 2. Proportion of patients with >10% and mean percent improvement in eGFR at 48 weeks from the baseline calculated by the four equations.
| Cases with >10% increase from baseline | P value (95% CI) | Mean % improvement in eGFR from baseline | Difference in mean % improvement (95% CI) (DRV/r + RAL versus LPV/r + TDF/FTC) |
P value | |
|---|---|---|---|---|---|
| CG equation | |||||
| DRV/r + RAL | 6/24 | 0.272 (-0.067 to 0.354) | 5.4% | -8.7% (-18.2 to 0.8) | 0.071 |
| LPV/r + TDF/FTC | 3/28 | -3.3% | |||
| JSN equation | |||||
| DRV/r + RAL | 4/24 | 0.688 (-0.126 to 0.267) | 2.5% | -1.1% (-6.9 to 4.8) | 0.720 |
| LPV/r + TDF/FTC | 3/29 | 1.5% | |||
| CKD-EPI equation | |||||
| DRV/r + RAL | 2/24 | 1.000 (-0.148 to 0.197) | 1.9% | -1.6% (-4.7 to 1.6) | 0.323 |
| LPV/r + TDF/FTC | 2/29 | 1.7% | |||
| MDRD equation | |||||
| DRV/r + RAL | 5/24 | 0.444 (-0.093 to 0.313) | 2.7% | -1.1% (-6.9 to 4.8) | 0.722 |
| LPV/r + TDF/FTC | 3/29 | 1.7% |
DRV/r: ritonavir-boosted darunavir, RAL: raltegravir, LPV/r: ritonavir-boosted lopinavir, TDF: tenofovir, FTC: emtricitabine, CG: Cockcroft-Gault equation [35], JSN: the Japanese Society of Nephrology equation [37], CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation adjusted for the Japanese[38], MDRD: the Modification of Diet in Renal Disease equation adjusted with coefficient for the Japanese [37]